<DOC>
	<DOCNO>NCT01041638</DOCNO>
	<brief_summary>This phase III trial study side effect give monoclonal antibody Ch14.18 together sargramostim , aldesleukin , isotretinoin autologous stem cell transplant treat patient neuroblastoma . Monoclonal antibody , Ch14.18 , may find tumor cell help kill . Colony-stimulating factor , sargramostim , may increase number immune cell find bone marrow peripheral blood . Aldesleukin may stimulate white blood cell kill tumor cell . Isotretinoin may help neuroblastoma cell become like normal cell , grow spread slowly . Giving monoclonal antibody Ch14.18 sargramostim , aldesleukin , isotretinoin autologous stem cell transplant may effective treatment neuroblastoma .</brief_summary>
	<brief_title>Monoclonal Antibody Ch14.18 , Sargramostim , Aldesleukin , Isotretinoin After Autologous Stem Cell Transplant Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To comprehensively define safety profile ch14.18 administer cytokine isotretinoin high-risk neuroblastoma patient autologous stem cell transplant ( ASCT ) . SECONDARY OBJECTIVES : I . To describe refine event-free survival ( EFS ) overall survival ( OS ) estimate baseline characteristic subject receive chl4.18 + cytokine + isotretinoin . II . To describe safety toxicity chl4.18 + cytokine + isotretinoin focus : ) number course deliver per patient ; b ) number dose reduction stoppage ( ch14.18 and/or interleukin [ IL ] -2 [ aldesleukin ] ) ; c ) number toxic death . III . To describe immune reconstitution patient follow ASCT , base laboratory data obtain prior , , treatment regimen . IV . To obtain correlative laboratory data evaluate describe mechanism related response , toxicity immune activation , allergic phenomenon . OUTLINE : Patients receive sargramostim subcutaneously ( SC ) intravenously ( IV ) 2 hour day 0-13 course 1 , 3 , 5 ; monoclonal antibody Ch14.18 IV 10 hour day 3-6 course 1 , 3 , 5 day 7-10 course 2 4 ; isotretinoin orally ( PO ) twice daily ( BID ) day 11-24 course 1 , day 14-27 course 2 , 4 , 6 , day 10-23 course 3 5 . Patients also receive aldesleukin IV continuously day 0-3 day 7-10 course 2 4 . Treatment repeat every 24-32 day 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 1 year , every 6 month 4 year , annually thereafter .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>All patient must diagnose neuroblastoma , categorize highrisk time diagnosis At preASCT evaluation , patient must meet International Neuroblastoma Response Criteria ( INRC ) complete response ( CR ) , good partial response ( VGPR ) , partial response ( PR ) primary site , soft tissue metastases bone metastasis ; patient meet criterion must also meet protocol specify criterion bone marrow response outline : = &lt; 10 % tumor ( total nucleate cellular content ) see specimen bilateral bone marrow aspirate/biopsy ; patient tumor see prior bone marrow , = &lt; 10 % tumor bilateral marrow aspirate/biopsy specimens do preASCT and/or preenrollment evaluation also eligible ; ( Note , per INRC , would define `` overall '' response progressive disease [ PD ] ) Prior enrollment ANBL0931 , determination residual disease must perform ( tumor image study include metaiodobenzylguanidine [ MIBG ] scan , compute tomography [ CT ] magnetic resonance image [ MRI ] , bone marrow aspiration biopsy ) ; disease assessment require eligibility , do preferably within 2 week must do within maximum 4 week enrollment Patients residual disease eligible ; biopsy required Patients must progressive disease except protocol specify bone marrow response All patient must complete therapy include intensive induction chemotherapy follow ASCT radiotherapy eligible ; radiotherapy may waive patient either small adrenal mass completely resect upfront , never identifiable primary tumor No 9 month date start first induction chemotherapy diagnosis date ASCT except rare occasion note ; tandem ASCT patient , date FIRST stem cell infusion ; Exception : initially diagnose nonhigh risk neuroblastoma , later convert ( and/ relapse ) high risk neuroblastoma , 9 month restriction start date induction therapy high risk neuroblastoma ( initial induction therapy nonhigh risk disease ) , date ASCT Use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age ; require patient must Lansky Karnofsky performance scale score &gt; = 50 % Patients must life expectancy &gt; = 2 month ( 8 week ) Total absolute phagocyte count ( APC = neutrophils + monocyte ) least 1000/uL Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : 1 month &lt; 6 month : 0.4 mg/dL 6 month &lt; 1 year : 0.5 mg/dL 1 &lt; 2 year : 0.6 mg/dL 2 &lt; 6 year : 0.8 mg/dL 6 &lt; 10 year : 1 mg/dL 10 &lt; 13 year : 1.2 mg/dL 13 &lt; 16 year : 1.5 mg/dL ( male ) , 1.4 mg/dL ( female ) &gt; = 16 year : 1.7 mg/dL ( male ) , 1.4 mg/dL ( female ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 5 x upper limit normal ( ULN ) age SOS ( sinusoidal obstruction syndrome , formerly know venoocclusive disease [ VOD ] ) , present , stable improve Shortening fraction &gt; = 27 % echocardiogram , ejection fraction &gt; = 55 % radionuclide angiography No evidence dyspnea rest If pulmonary function test ( PFTs ) perform , force expiratory volume one second ( FEV1 ) /forced vital capacity ( FVC ) &gt; 60 % pulmonary function test Patients seizure disorder may enrol anticonvulsant well controlled Central nervous system ( CNS ) toxicity &lt; grade 2 Females childbearing potential must negative pregnancy test Patients childbearing potential must agree use effective birth control method Female patient lactate must agree stop breastfeeding Patients must receive prior antiGD2 antibody therapy Patients must receive prior vaccine therapy administer treatment neuroblastoma routine infectious disease vaccination</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>